To inhibit the escape, proliferation, and metastasis of tumor cells.[14,15] Single drug first-line treatment with PD-1/PD-L1 inhibitors was obtained in advanced NSCLC that achieved better efficacy in the Keynote024 clinical trial.[16] Similar results were also shown in the BIRCH clinical trial with natalizumab which has a better curative effect than radiotherapy.[17]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.